

## LISTING OF THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in this application.

1-75. (Canceled)

76. (Previously presented) A method of treating fibromyalgia syndrome (FMS) and/or physiological symptoms associated therewith in an animal subject suffering from FMS, comprising administering to said animal subject, an effective amount for treating FMS of milnacipran, or a pharmaceutically acceptable salt thereof, in combination with a compound that is not phenylalanine, tyrosine and/or tryptophan.

77. (Previously presented) The method of claim 76, wherein the milnacipran is administered in combination with an antidepressant, analgesic, muscle relaxant, anorectic, stimulant, antiepileptic drug, sedative, or hypnotic.

78. (Previously presented) The method of claim 76, wherein the milnacipran is administered in combination with neurontin, pregabalin, pramipexole, L-DOPA, amphetamine, tizanidine, clonidine, tramadol, morphine, codeine, carbamazepine, sibutramine, valium, or trazodone.

79. (Previously presented) The method of claim 76, wherein the animal is a human.

80. (Previously presented) The method of claim 76, wherein the amount administered is from about 25 mg to about 400 mg per day.

81. (Previously presented) The method according to claim 76, wherein milnacipran is formulated in a sustained release dosage formulation.

82. (Previously presented) A method of treating pain in an animal subject suffering from pain, comprising administering to said animal subject, an effective amount for treating pain of milnacipran, or a pharmaceutically acceptable salt thereof, in combination with an analgesic, muscle relaxant, anorectic, stimulant, antiepileptic drug, or hypnotic.

83. (Canceled)

84. (Previously presented) A method of treating pain in an animal subject suffering from pain, comprising administering to said animal subject, an effective amount for treating pain of milnacipran, or a pharmaceutically acceptable salt thereof, in combination with neurontin, pregabalin, pramipexole, l-DOPA, amphetamine, tizanidine, clonidine, tramadol, morphine, codeine, carbamazepine, sibutramine, valium, or trazodone.

85. (Previously presented) The method of claim 84, wherein the animal is a human.

86. (Previously presented) The method of claim 84, wherein the amount administered is from about 25 mg to about 400 mg per day.

87. (Previously presented) The method according to claim 84, wherein milnacipran is formulated in a sustained release dosage formulation.

88. (Previously presented) A method of treating chronic fatigue syndrome (CFS) and/or physiological symptoms associated therewith in an animal subject afflicted with CFS, comprising administering to said animal subject, an effective amount for treating CFS of milnacipran, or a pharmaceutically acceptable salt thereof, in combination with an analgesic, muscle relaxant, anorectic, stimulant, antiepileptic drug, or hypnotic.

89. (Canceled)

90. (Previously presented) A method of treating chronic fatigue syndrome (CFS) and/or physiological symptoms associated therewith in an animal subject afflicted with CFS, comprising administering to said animal subject, an effective amount for treating CFS of milnacipran, or a pharmaceutically acceptable salt thereof, in combination with neurontin, pregabalin, pramipexole, l-DOPA, amphetamine, tizanidine, clonidine, tramadol, morphine, codeine, carbamazepine, sibutramine, valium, or trazodone.

91. (Previously presented) The method of claim 88, wherein the animal is a human.

92. (Previously presented) The method of claim 88, wherein the amount administered is from about 25 mg to about 400 mg per day.
93. (Previously presented) The method according to claim 88, wherein milnacipran is formulated in a sustained release dosage formulation.
94. (New) A method of treating fibromyalgia syndrome (FMS) and/or physiological symptoms associated therewith in an animal subject suffering from FMS, comprising administering to said animal subject, an effective amount for treating FMS of milnacipran, or a pharmaceutically acceptable salt thereof, in combination with an analgesic, muscle relaxant, anorectic, stimulant, antiepileptic drug, sedative, or hypnotic.
95. (New) A method of treating fibromyalgia syndrome (FMS) and/or physiological symptoms associated therewith in an animal subject suffering from FMS, comprising administering to said animal subject, an effective amount for treating FMS of milnacipran, or a pharmaceutically acceptable salt thereof, in combination with neurontin, pregabalin, pramipexole, l-DOPA, amphetamine, tizanidine, clonidine, tramadol, morphine, codeine, carbamazepine, sibutramine, valium, or trazodone.
96. (New) The method of claim 94, wherein the animal is a human.
97. (New) The method of claim 94, wherein the amount administered is from about 25 mg to about 400 mg per day.
98. (New) The method according to claim 94, wherein milnacipran is formulated in a sustained release dosage formulation.